Cholangiocarcinoma – Epidemiology – Mature Markets
Clarivate Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of cholangiocarcinoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the major mature pharmaceutical markets.
Clarivate Epidemiology's cholangiocarcinoma forecast will answer the question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of soft tissue sarcoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following cholangiocarcinoma subpopulations:
- Diagnosed incident cases: cholangiocarcinoma.
- Diagnosed incident cases: intrahepatic and extrahepatic cholangiocarcinoma.
- Diagnosed incident cases by stage scheme: cholangiocarcinoma (resectable and unresectable).
- Diagnosed incident cases by stage scheme: intrahepatic and extrahepatic cholangiocarcinoma (resectable and unresectable).
- Recurrent incident cases: cholangiocarcinoma.
- Recurrent incident cases: intrahepatic and extrahepatic cholangiocarcinoma.
- Diagnosed prevalent cases: cholangiocarcinoma.
- Diagnosed prevalent cases: intrahepatic and extrahepatic cholangiocarcinoma.
- First-line drug-treatable cases: cholangiocarcinoma.
- First-line drug-treatable cases: intrahepatic and extrahepatic cholangiocarcinoma.
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Cholangiocarcinoma - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Overview
- Incidence of Cholangiocarcinoma per 100,000 per Year Among People of All Ages in 2021 and 2041ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Cholangiocarcinoma over the Next 20 Yearsttttttttt
- Analysis of the Incident Cases of Cholangiocarcinoma in 2021 by Origin Tissuettttttttttttttttt
- Analysis of the Incident Cases of Intrahepatic and Extrahepatic Cholangiocarcinoma in 2021 by Resectability Statusttttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Incidence
- Stage Distribution
- Recurrent Incidence
- Diagnose Prevalence
- Drug-Treatable Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Cholangiocarcinoma
- Studies Excluded from the Analysis of Cholangiocarcinoma
- Risk/Protective Factors
- Risk/Protective Factors for Cholangiocarcinoma
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Jai Oberoi, M.P.H., is an associate epidemiologist at Clarivate. Previously, he was a research specialist at Emory University, where he analyzed whole genome/exome data. He obtained his M.P.H. in epidemiology and applied biostatistics from Columbia University, where he conducted research on the phenotypic and genotypic markers of aging.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.